Non-small Cell Lung Cancer Stage I
Conditions
Brief summary
Lung cancer is the leading cause of cancer related mortality. At present, surgical treatment is the main choice for early-stage lung cancer. Even after surgery, the 5-year recurrence rate is still as high as 18.4%-24%. Traditional Chinese medicine combined with thermal and cold ablation could be an alternative treatment. Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. The primary aim of this trial is to evaluate the efficacy of traditional Chinese medicine combined with thermal and cold ablation for patients with stage I non-small cell lung cancer.
Interventions
COMBINATION_PRODUCTtraditional Chinese medicine and ablation in the primary tumor sites
Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
PROCEDUREablation
Patients will be treated with ablation in the primary tumor sites
Sponsors
Shanghai 10th People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good. * Patients with lung nodule. * Maximum diameter of lung nodule ≥8mm. * The pathology of lung nodules biopsy was non-small cell lung cancer. * I period according to the eighth edition of the TNM staging period. * No mediastinal lymph node metastasis. * Eastern Cooperative Oncology Group performance status of 0 to 1. * No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments. * Sufficient organ functions.
Exclusion criteria
* Patients with previous use of various hormones, immunosuppression or autoimmune diseases. * Women during pregnancy or breast-feeding. * Patients with severe heart, lung, kidney disease or other systemic diseases * Patients with severe hemorrhagic diseases. * Patients with a history of drug abuse or mental illness. * Other conditions that the investigator has determined are not suitable for participation in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | 2 years after ablation | Response were evaluated in this study using the revised international criteria (1.1) proposed by the RECIST (Response Evaluation Criteria in Solid Tumours) committee. BEST RESPONSE from the start of study treatment until the end of treatment were reported. Objective response rate is the sum of CR + PR divided by the total number of patients in each group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DFS | 2 years after ablation | The time interval from the first medication to the observation of recurrence or metastasis, or death from any cause (calculated based on the previous event). Patients who have not relapsed, metastasized or died at the time of the data cutoff, and those who were lost to follow-up in the study will be counted on the date of their last tumor evaluation. |
Countries
China
Contacts
Primary ContactLihong Fan, M.D.
Outcome results
None listed